Frank Löscher
Chief Executive Officer at Dermaliq Therapeutics, Inc.
Frank Löscher active positions
| Companies | Position | Start | End |
|---|---|---|---|
Novaliq GmbH
 Novaliq GmbH Medical SpecialtiesHealth Technology Novaliq GmbH develops and markets drug delivery systems. The firm specializes in the development of novel pharmaceutical formulations based on semifluorinated alkanes . It product pipeline encompasses the NovaTears, CyckAol, and I-Let Protect technologies. The company was founded in 2004 and is headquartered in Heidelberg, Germany. | Chief Tech/Sci/R&D Officer | - | - |
| Corporate Officer/Principal | - | - | |
Dermaliq Therapeutics, Inc.
 Dermaliq Therapeutics, Inc. Information Technology ServicesTechnology Services Dermaliq Therapeutics, Inc. is a clinical stage pharmaceutical company based in Wilmington, DE, USA. Dermaliq has signed a USD 15 million series A round to advance three transformative skin care drug therapies through clinical trials. Key shareholders are Novaliq GmbH, 3E Bioventures Capital, and Whale Technology Corporation Ltd. The company was founded in 2021 through a spin-off from Novaliq GmbH to develop a new generation of superior topical drug therapies and medical skin care products with greater efficacy and fewer unwanted side effects for millions of patients. The CEO of the company is Frank Lösher. | Chief Executive Officer | - | - |
| President | - | - |
Career history of Frank Löscher
Training of Frank Löscher
| Ruprecht-Karls-Universität Heidelberg | Undergraduate Degree |
| University of Regensburg | Doctorate Degree |
Statistics
International
| Germany | 4 |
| United States | 2 |
Operational
| Chief Tech/Sci/R&D Officer | 1 |
| Corporate Officer/Principal | 1 |
| Doctorate Degree | 1 |
Sectoral
| Consumer Services | 3 |
| Health Technology | 2 |
| Technology Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 2 |
|---|---|
Novaliq GmbH
Novaliq GmbH Medical SpecialtiesHealth Technology Novaliq GmbH develops and markets drug delivery systems. The firm specializes in the development of novel pharmaceutical formulations based on semifluorinated alkanes . It product pipeline encompasses the NovaTears, CyckAol, and I-Let Protect technologies. The company was founded in 2004 and is headquartered in Heidelberg, Germany. | Health Technology |
Dermaliq Therapeutics, Inc.
Dermaliq Therapeutics, Inc. Information Technology ServicesTechnology Services Dermaliq Therapeutics, Inc. is a clinical stage pharmaceutical company based in Wilmington, DE, USA. Dermaliq has signed a USD 15 million series A round to advance three transformative skin care drug therapies through clinical trials. Key shareholders are Novaliq GmbH, 3E Bioventures Capital, and Whale Technology Corporation Ltd. The company was founded in 2021 through a spin-off from Novaliq GmbH to develop a new generation of superior topical drug therapies and medical skin care products with greater efficacy and fewer unwanted side effects for millions of patients. The CEO of the company is Frank Lösher. | Technology Services |
- Stock Market
- Insiders
- Frank Löscher
- Experience
